CollPlant Biotechnologies (NASDAQ:CLGN) Receives “Hold” Rating from D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “hold” rating reiterated by investment analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CollPlant Biotechnologies presently has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Trading Down 53.4%

NASDAQ CLGN opened at $0.75 on Friday. The business’s 50 day moving average is $1.65 and its two-hundred day moving average is $2.16. CollPlant Biotechnologies has a 12-month low of $0.66 and a 12-month high of $4.98. The stock has a market capitalization of $9.59 million, a price-to-earnings ratio of -0.74 and a beta of 2.28.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings results on Wednesday, November 26th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.65). CollPlant Biotechnologies had a negative net margin of 491.31% and a negative return on equity of 102.00%. The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $16.52 million. Equities analysts forecast that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Institutional Trading of CollPlant Biotechnologies

Large investors have recently modified their holdings of the business. Villere ST Denis J & Co. LLC lifted its holdings in shares of CollPlant Biotechnologies by 3.2% during the 4th quarter. Villere ST Denis J & Co. LLC now owns 607,300 shares of the company’s stock worth $850,000 after acquiring an additional 18,583 shares during the period. Pinnacle Associates Ltd. raised its stake in CollPlant Biotechnologies by 9.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 557,193 shares of the company’s stock worth $780,000 after purchasing an additional 50,000 shares during the period. Finally, AMH Equity Ltd raised its stake in CollPlant Biotechnologies by 24.3% during the third quarter. AMH Equity Ltd now owns 200,000 shares of the company’s stock worth $538,000 after purchasing an additional 39,151 shares during the period. 21.69% of the stock is currently owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.